Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
Pediatric Cancer
Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
Repotrectinib Plus Chemotherapy in Patients With Relapsed/Refractory Solid Tumors
Researchers are conducting a phase 1/2 trial to assess the safety and efficacy of combination repotrectinib, irinotecan, and temozolomide.
RRx-001 Plus Chemotherapy in Recurrent/Progressive Solid Tumors
Researchers are conducting a phase 1 trial to assess the safety and efficacy of RRx-001 in combination with irinotecan and temozolomide.
Ibrutinib Plus Chemoimmunotherapy for Patients With Brain Cancer
Researchers are conducting a phase 1 trial of ibrutinib plus indoximod, cyclophosphamide, and etoposide in patients with brain cancers.
Nivatrotamab in Patients With Relapsed/Refractory Solid Tumors
Researchers will assess toxicity and pharmacokinetics in phase 1 and the antitumor activity of nivatrotamab in phase 2.
Brentuximab Vedotin Improves Outcomes in Pediatric High-Risk Classic Hodgkin Lymphoma
Results of a phase 3 trial suggest that brentuximab vedotin (Bv) with doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) should be the new standard frontline therapy among youth with high-risk classic Hodgkin lymphoma (cHL).
Upfront Radiotherapy May Benefit Medulloblastoma Patients With Li-Fraumeni Syndrome
Patients with sonic hedgehog medulloblastoma and Li-Fraumeni syndrome have a “dismal” prognosis, according to researchers.
Reinduction Regimen Appears Effective in Children With Relapsed Medulloblastoma
The overall response rate after 2 treatment cycles was 78%.
RNA Sequencing Reveals Clinically Relevant Alterations in Pediatric Low-Grade Glioma
RNA sequencing confirmed the alterations most frequently described in low-grade glioma and revealed rare gene fusions.
- Loading...
Loading...
Next post in ISPNO 2022
Loading... 
Loading...